Sasaki H, Maekawa I, Kawamura S, Miyake T
Hokkaido Igaku Zasshi. 1983 May;58(3):271-8.
We analysed the effects of three different regimens for first induction therapy with 50 cases of acute nonlymphocytic leukemia in adults and reported the results of combination therapy including aclacinomycin for reinduction therapy. Results obtained were as follows: The regimens of DCMP 2 step and Cc, P were superior to DCMP in remission rate (78%, 78% and 41%), median duration of CR (8.3 months, 5.0 months and 3.5 months) and survival time (6.5 months, 11.5 months and 2 months). Cc, P regimens obtained favorable CR rate in elderly patients over 50 years of age. (Cc, P: 100%, others: 40-50%) No significant difference in survival time was observed in patients who attained CR by three different regimens. In patients treated with combination therapy including aclacinomycin, the CR rate was 89% in the 9 previously treated patients (5 relapse cases and 4 refractory leukemias): All of these patients had previously been treated with DCMP 2 step or BHAC-DMP. Daunomycin (D), Cytosine Arabinoside (C), 6-Mercaptopurine (M) and Prednisolone (P) (DCMP), DCMP 2 step and Cyclocytidine (Cc) P.
我们分析了三种不同诱导治疗方案对50例成人急性非淋巴细胞白血病的疗效,并报告了包括阿克拉霉素再诱导治疗的联合治疗结果。获得的结果如下:DCMP二步方案和Cc、P方案在缓解率(78%、78%和41%)、完全缓解(CR)的中位持续时间(8.3个月、5.0个月和3.5个月)和生存时间(6.5个月、11.5个月和2个月)方面优于DCMP方案。Cc、P方案在50岁以上老年患者中获得了良好的CR率。(Cc、P:100%,其他:40 - 50%)三种不同方案达到CR的患者生存时间无显著差异。在接受包括阿克拉霉素的联合治疗的患者中,9例既往治疗过的患者(5例复发和4例难治性白血病)的CR率为89%:所有这些患者既往均接受过DCMP二步方案或BHAC - DMP治疗。柔红霉素(D)、阿糖胞苷(C)、6 - 巯基嘌呤(M)和泼尼松龙(P)(DCMP)、DCMP二步方案和环胞苷(Cc)P。